224 episodes

Podcast by STAT

The Readout Loud STAT

    • Business
    • 4.9 • 11 Ratings

Podcast by STAT

    Episode 222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment

    Episode 222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment

    First, STAT's Tara Bannow joins us to discuss how private equity's mounting interest in autism care has created an untenable situation for many parents in the U.S. We also explain the implications of Bluebird Bio's long-awaited FDA approval, a controversial treatment for ALS, and the ups and downs of Merck's reported interest in buying Seagen.

    • 29 min
    Episode 221: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing

    Episode 221: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing

    Are biotech's fortunes finally changing? Is Big Science impeding actual science? And what will Medicare negotiation mean for drug prices? STAT's Jason Mast joins us to discuss Jim Wilson, a pioneering scientist synonymous with the rise of gene therapy who staffers say presided over a toxic, abusive workplace. We also explain the latest news in the life sciences, including a multibillion-dollar deal, a novel approach to treating schizophrenia, and what the Senate drug pricing legislation means for the pharmaceutical industry.

    • 29 min
    Episode 220: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble

    Episode 220: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble

    Is drug pricing reform really happening this time? Are things finally turning around for biotech? And is it ever wise to tweet your food? Rachel Cohrs, STAT's Washington correspondent, joins us to explain how congressional Democrats are on the verge of a coup in drug pricing — and what could still stand in their way. We also discuss the latest news in the life sciences, including some hotly anticipated data from Alnylam Pharmaceuticals, a $4 billion buyout deal, and other surprisingly good news for biotech.

    • 33 min
    219: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer's data

    219: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer's data

    Can monkeypox be contained? Are snortable Covid-19 vaccines on the way? And when is a GIF worth $200,000? STAT's Helen Branswell joins us to explain the latest in the monkeypox outbreak and how health authorities are struggling to contain it. We also discuss the latest news in the life sciences, including some faked Alzheimer’s data, a brewing FDA controversy, and what it means when a scientific discovery gets turned into an NFT.

    • 35 min
    218: Well-paid CEOs, behind the scenes at Moderna, & Biogen's CEO search

    218: Well-paid CEOs, behind the scenes at Moderna, & Biogen's CEO search

    Does any CEO deserve $500 million a year? How did Moderna hit it big? And who wants to run Biogen? STAT's Bob Herman joins us to explain why health care CEOs get paid so much — and why company-reported numbers don't tell the full story. Wall Street Journal reporter Peter Loftus calls in to talk about his book chronicling how Moderna went from secretive startup to household name. And we discuss the latest news in the life sciences, including Amazon's latest multibillion-dollar foray into primary care and Biogen's search for a new CEO.

    • 38 min
    217: CRISPR for the heart, biotech's recovery, & what it means to be a 'hot girl'

    217: CRISPR for the heart, biotech's recovery, & what it means to be a 'hot girl'

    Can CRISPR edit out a heart attack? What happens on #GutTok? And is health care recession-proof? Sek Kathiresan, cardiologist and CEO of Verve Therapeutics, joins us to explain the company's work on preventing heart disease with genome editing. Then, STAT's Isabella Cueto joins us to discuss "Hot girls have IBS," an internet in-joke that evolved into a movement for people with chronic illness. We also break down the latest news in the life sciences, including a long-awaited victory for Novavax and ostensible good news for biotech.

    • 30 min

Customer Reviews

4.9 out of 5
11 Ratings

11 Ratings

torrich75 ,

Outstanding podcast for anyone in pharma/biotech/health policy

The readout loud by stat is without doubt the best podcast out there for those interested in getting a short but entertaining weekly view on what’s happening in the world of pharma and biotech. The presenters are engaging and effective at explaining sometimes obscure concepts in a way that make sense to the listener. The choice of topics is always up to date and relevant and I particularly appreciate the fact that the tone is always fair, objective and balanced.
Thanks to the stat team for the energy you put into this. Keep it up. I, for one, don’t miss an episode.

You Might Also Like

Timmerman Report
BioCentury
Kaiser Health News
Tradeoffs
Vincent Racaniello
The Wall Street Journal & Gimlet